Featured Research

from universities, journals, and other organizations

NIAID And The Malaria Vaccine Initiative/Path Sign Agreement To Accelerate Malaria Vaccine Research

Date:
February 22, 2000
Source:
National Institute Of Allergy And Infectious Diseases
Summary:
The National Institute of Allergy and Infectious Diseases (NIAID) and the Malaria Vaccine Initiative (MVI) at PATH plan to speed development of malaria vaccines. Malaria is an enormous public health burden in many developing countries, one that has worsened in recent decades as some strains of the malaria parasite have developed resistance to drug treatments and mosquitoes have become impervious to insecticides.

The National Institute of Allergy and Infectious Diseases (NIAID) and the Malaria Vaccine Initiative (MVI) at PATH today (Feb. 14) announced they have signed a Memorandum of Understanding (MOU) to speed development of malaria vaccines. The agreement opens the way for greater collaboration in malaria vaccine research between NIAID and MVI. Last year, PATH (Program for Appropriate Technology in Health), a Seattle-based, nonprofit organization, established MVI through a $50-million grant from the Bill and Melinda Gates Foundation to help remove critical barriers to getting a safe and effective malaria vaccine into widespread use.

"This cooperative relationship is a model of how government can work with private organizations to invest in research that could save millions of lives," says NIAID Director Anthony S. Fauci, M.D. "NIAID has a long-standing commitment to investigating the treatment and prevention of malaria, and we welcome this opportunity to advance efforts toward a malaria vaccine."

Each year, malaria kills about 2 million people, mostly children-a child dies from malaria every 30 seconds. More than 300 million victims suffer crippling fevers and other health problems from the disease, which is caused by a parasite transmitted by mosquito bites. Malaria is an enormous public health burden in many developing countries, one that has worsened in recent decades as some strains of the malaria parasite have developed resistance to drug treatments and mosquitoes have become impervious to insecticides.

MVI, headquartered in Rockville, MD, seeks to accelerate the clinical development of promising malaria vaccine candidates by coordinating efforts with organizations such as NIAID. "The signing of this first MOU is a critical step in establishing a series of agreements that will allow MVI to have an impact on malaria vaccine research," says MVI Director Regina Rabinovich, M.D. "NIAID offers unparalleled clinical testing sites for malaria vaccines and a growing capability to manufacture sufficient quantities of vaccine for field-testing. Its broad capacity, partnered with MVI, will help make malaria vaccines available and accessible to people throughout the world sooner rather than later."

NIAID began investigating malaria over 50 years ago, and today the Institute is the world's leading supporter of malaria research. NIAID-supported scientists conduct laboratory and clinical research, including field-based studies of malaria in endemic areas of Africa and Southeast Asia, such as Mali, Ghana, Malawi and Papua New Guinea. In 1997, NIAID developed a multiyear plan to accelerate malaria vaccine research. In keeping with its goals, recent initiatives have been marked by several milestones:

**the launch of an Internet-based resource center for malaria research reagents;

**preclinical and clinical testing of promising vaccine candidates; and

**the publication of a detailed genetic map of the malaria parasite.

NIAID is also pursuing studies on the human immune response to malaria, establishing clinical research and trial preparation sites in endemic regions, and promoting collaborative efforts for vaccine discovery, production and evaluation.

One such partnership is spelled out in the new Memorandum of Understanding. Together, MVI and NIAID will develop joint work plans for targeted activities to be funded by MVI. At its discretion, MVI will direct funding for NIAID-administered programs to the Foundation for the National Institutes of Health (NIH). The Congressionally created Foundation, which also signed the agreement, fosters collaborative relationships in education, research and related activities among NIH, industry, academia and nonprofit organizations. Another party to the agreement is the NIH Office of Technology Transfer, which will oversee patents and inventions that might arise from research conducted in government laboratories.

MVI is a special program managed by PATH, whose mission is to improve health, especially the health of women and children.

NIAID is a component of the National Institutes of Health (NIH). NIAID conducts and supports research to prevent, diagnose and treat illnesses such as HIV disease and other sexually transmitted diseases, tuberculosis, malaria, asthma and allergies. NIH is an agency of the U.S. Department of Health and Human Services.

Press releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov. For more information on malaria, please visit NIAID's malaria publications page.


Story Source:

The above story is based on materials provided by National Institute Of Allergy And Infectious Diseases. Note: Materials may be edited for content and length.


Cite This Page:

National Institute Of Allergy And Infectious Diseases. "NIAID And The Malaria Vaccine Initiative/Path Sign Agreement To Accelerate Malaria Vaccine Research." ScienceDaily. ScienceDaily, 22 February 2000. <www.sciencedaily.com/releases/2000/02/000214101246.htm>.
National Institute Of Allergy And Infectious Diseases. (2000, February 22). NIAID And The Malaria Vaccine Initiative/Path Sign Agreement To Accelerate Malaria Vaccine Research. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2000/02/000214101246.htm
National Institute Of Allergy And Infectious Diseases. "NIAID And The Malaria Vaccine Initiative/Path Sign Agreement To Accelerate Malaria Vaccine Research." ScienceDaily. www.sciencedaily.com/releases/2000/02/000214101246.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pregnancy Spacing Could Have Big Impact On Autism Risks

Pregnancy Spacing Could Have Big Impact On Autism Risks

Newsy (Oct. 1, 2014) A new study says children born less than one year and more than five years after a sibling can have an increased risk for autism. Video provided by Newsy
Powered by NewsLook.com
Robotic Hair Restoration

Robotic Hair Restoration

Ivanhoe (Oct. 1, 2014) A new robotic procedure is changing the way we transplant hair. The ARTAS robot leaves no linear scarring and provides more natural results. Video provided by Ivanhoe
Powered by NewsLook.com
Insertable Cardiac Monitor

Insertable Cardiac Monitor

Ivanhoe (Oct. 1, 2014) A heart monitor the size of a paperclip that can save your life. The “Reveal Linq” allows a doctor to monitor patients with A-Fib on a continuous basis for up to 3 years! Video provided by Ivanhoe
Powered by NewsLook.com
Attacking Superbugs

Attacking Superbugs

Ivanhoe (Oct. 1, 2014) Two weapons hospitals can use to attack superbugs. Scientists in Ireland created a new gel resistant to superbugs, and a robot that can disinfect a room in minutes. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins